The European research-based pharma industry federation EFPIA is warning that the “drastic” new criteria for the price-setting of original drugs adopted in Japan in April are unduly focused on short-term government cost savings, and are already prompting some its local members to revise their R&D strategies given increased business uncertainty.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?